Abstract | AIMS: METHODS AND RESULTS: HOMAGE evaluated the effect of spironolactone on plasma and serum markers of fibrosis over 9 months of follow-up in participants with (or at risk of having) CAD, and raised natriuretic peptides. In this post hoc analysis, patients were classified as (i) neither CAD nor MI; (ii) CAD; or (iii) MI. Proteomic between-group differences were evaluated through logistic regression and narrowed using backward stepwise selection and bootstrapping. Among the 527 participants, 28% had neither CAD or MI, 31% had CAD, and 41% had prior MI. Compared with people with neither CAD nor MI, those with CAD had higher baseline plasma concentrations of matrix metalloproteinase-7 (MMP-7), galectin-4 (GAL4), plasminogen activator inhibitor 1 (PAI-1), and lower plasma peptidoglycan recognition protein 1 (PGLYRP1), whilst those with a history of MI had higher plasma MMP-7, neurotrophin-3 (NT3), pulmonary surfactant-associated protein D (PSPD), and lower plasma tumour necrosis factor-related activation-induced cytokine (TRANCE). Proteomic signatures were similar for patients with CAD or prior MI. Treatment with spironolactone was associated with an increase of MMP7, NT3, and PGLYRP1 at 9 months. CONCLUSIONS: In patients at risk of developing HF, those with CAD or MI had a different proteomic profile regarding inflammatory, immunological, and collagen catabolic processes.
|
Authors | Diogo Santos-Ferreira, Sílvia O Diaz, João Pedro Ferreira, Nicolas Girerd, Pierpaolo Pellicori, Beatrice Mariottoni, Franco Cosmi, Mark Hazebroek, Job A J Verdonschot, Joe Cuthbert, Johannes Petutschnigg, Stephane Heymans, Jan A Staessen, Burkert Pieske, Frank Edelmann, Andrew L Clark, Patrick Rossignol, Ricardo Fontes-Carvalho, John G F Cleland, Faiez Zannad |
Journal | ESC heart failure
(ESC Heart Fail)
Vol. 11
Issue 1
Pg. 209-218
(Feb 2024)
ISSN: 2055-5822 [Electronic] England |
PMID | 37939716
(Publication Type: Journal Article)
|
Copyright | © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. |
Chemical References |
- Matrix Metalloproteinase 7
- Spironolactone
|
Topics |
- Humans
- Coronary Artery Disease
(complications)
- Matrix Metalloproteinase 7
(therapeutic use)
- Spironolactone
(therapeutic use)
- Proteomics
- Myocardial Infarction
(complications)
- Heart Failure
(complications)
|